Medical System Network (4350) · RiskRestated
Risks relating to approvals, licenses, adverse effects and quality incidents involving generic drugs
First written in FY2018. 2 of 3 entries say "Restated". Latest entry: FY2022.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Risk of Product Recalls and Regulatory Action Due to Serious Quality IssuesA theme 97 companies write about · 98 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 13 of 36 companies on the "Worse" side.
54 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 97 companies compared. The sentences above are computed from all 97.Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「If an incident such as an unexpected new adverse effect or contamination of a product with impurities occurs, we may be forced to recall the product and discontinue its sale.」
The risks of quality incidents involving generic drugs, including adverse effects, contamination with impurities, product recalls and sales discontinuation, continue. - FY2021RestatedAnnual report
「If an incident such as an unexpected new adverse effect or contamination of a product with impurities occurs, we may be forced to recall the product and discontinue its sale.」
The risks of quality incidents involving generic drugs, including adverse effects, contamination with impurities, product recalls and sales discontinuation, continue to be described. - FY2018First statedAnnual report
「However, if an incident such as an unexpected new adverse effect or contamination of a product with impurities occurs, we may be forced to recall the product and discontinue its sale.」
For the manufacture and sale of generic drugs, the risks of revocation of approvals and licenses, suspension of operations, unexpected adverse effects, contamination with impurities, product recalls and sales discontinuation are newly described.